Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, affecting 24% of the population, and is impacting on global public health care with a considerable financial burden (1) . NAFLD encompasses a wide disease spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Patients with simple steatosis typically do not develop liver-related complications, whereas patients with NASH are at increased risk of hepatic and extra-hepatic mortality.
Furthermore, NAFLD is associated with an increased risk of type 2 diabetes, cardiovascular disease and cancer (2) . In addition, NASH is the second leading cause of cirrhosis in adult patients on the liver transplant waiting list in the United States (3, 4) . The review did not comment on the current mainstay strategy for NASH treatment, which is weight reduction through lifestyle interventions. These include a combination of increase in exercise/physical activity and caloric restriction and should be individually tailored. Weight loss of ≥7% of total body weight is associated with improvement in histologic features of NASH, while a weight loss of ≥10% is associated with fibrosis regression regardless of the method used (11).
Previous randomized controlled trials in NASH reported a histological improvement in the placebo arm that ranges between 10-30%. Although it is difficult to fully explain this, it is probable that a significant proportion of these patients improved due to the successful implementation of lifestyle changes.
Unhealthy lifestyle habits, such as smoking might be associated with more severe liver fibrosis and increased incidence of cardiovascular outcomes (12) . However, this approach is difficult to sustain, as most patients have low compliance to weight loss maintenance in the long term. To improve the efficacy and sustainability of this strategy, a multidisciplinary team approach is needed that includes primary care physicians, hepatologists, dietitians, physical trainers and psychologists. Bariatric surgery is a promising option for reducing weight and metabolic complications. Although it is not yet an established therapy for NASH and more data are required to support its use for the liver disease component, some experts suggest considering bariatric surgery in morbidly obese non-cirrhotic patients who failed lifestyle modifications (13).
In conclusion, the growing burden of NAFLD worldwide is an emerging concern. NASH is classified as a medical condition of an immediate unmet therapeutic need. Therefore continuous research is required in order to better understand its pathogenesis, develop of non-invasive markers of severity and identify new therapeutic targets.
